Stephen K. L. Chia

MD, FRCPC

Professor of Medicine
Medical Oncology
British Columbia Cancer Agency
University of British Columbia
Co-chair CCTG Breast Disease Site
Vancouver (BC)

Joyce A O’Shaughnessy

MD

Celebrating Women Endowed
Chair in Breast Cancer Research
Co-Chair, Breast Cancer Research Program
Chair, Breast Cancer Prevention Research
Baylor University Medical Center
Texas Oncology/US Oncology Network
Dallas (TX)

Christine Brezden-Masley

MD, PhD, FRCPC

Medical Oncologist, St. Michael’s Hospital
Associate Professor, University of Toronto
Co-Director, Hem. Oncology Clinical Research Group
Associate Scientist, Li Ka Shing Knowledge Institute
President, Canadian Cardio-Oncology Network
Founder, COMET Clinical Trials Consortium Consortium
Toronto (ON)

Scott Edwards

PharmD, MSc (Oncol)

Clinical Oncology Pharmacy Specialist
Cancer Care Program,
Eastern Health Assistant Professor,
Memorial University
St. John’s (NL)
This website is independent of the CBCS conference and developed to facilitate registration to the Satellite Symposia sponsored by Eli Lilly Canada Inc

DATE

Thursday, June 13, 2019
You must be registered for the CBCS conference to attend this satellite symposium

TIME

5 – 6 PM (Refreshments will be served)

LOCATION

Queen's Quay Room — The Westin Harbour Castle, Toronto

ABOUT THE SYMPOSIUM

This symposium will engage clinicians to optimize the management of patients with HR+/HER2- mBC being treated with CDK4/6 inhibitors in order to achieve best clinical outcomes. Presenters include both Canadian and US experts who share their clinical experiences through interview questions and interactive case-based presentations and discussions.


LEARNING OBJECTIVES

At the end of this learning activity, participants will be able to:
  • Review the latest evidence and ongoing research in the area of HR+/HER2- metastatic breast cancer to achieve best outcomes for these patients
  • Recognize best practices in the treatment of metastatic breast cancer with CDK4/6 inhibitors through discussions with experts in US and Canada
  • Explore heterogeneity in HR+/HER2- metastatic breast cancer and its implications for treatment choices through case discussions

REGISTRATION